Skip to main content

Table 3 Comparison of observed bevacizumab serum concentrations (unit: μg/mL) in the current study to predicted data

From: Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

   

Mean Concentration (95% Confidence Interval)

 

Time

 

Day 1

Day 15

Day 29

Day 43

Day 57

Day 85

Peak

Study Subjects

203

(181-225)

237

(211-263)

297

(268-325)

280

(232-328)

272

(231-313)

333

(300-366)

 

Predicted from PopPK

256

(147-405)

317

(172-497)

356

(196-569)

378

(212-616)

392

(212-628)

404

(207-664)

Trough

Study Subjects

N/Aa

35.4

(31.5-39.4)

74.3

(66.7-82.0)

84.7

(60.4-109)

97.7

(71.3-124)

119

(95.4-142)

 

Predicted from PopPK

N/A

58.2

(23.6-103)

95.6

(43.1-171)

122

(50.9-232)

139

(51.3-270)

156

(60.0-323)

Time

 

Day 8

Day 11

    

Other

Study Subjects

83.2

(71.7-94.6)

60.9

(53.2-68.6)

    
 

Predicted from PopPK

78.8

(34.4-138)

67.8

(27.9-123)

    
  1. a N/A is 'not applicable'.